Key Financial Inc Sells 250 Shares of Moderna, Inc. (NASDAQ:MRNA)

Key Financial Inc reduced its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 37.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 426 shares of the company’s stock after selling 250 shares during the quarter. Key Financial Inc’s holdings in Moderna were worth $42,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Cim Investment Management Inc. boosted its holdings in Moderna by 4.2% in the first quarter. Cim Investment Management Inc. now owns 2,139 shares of the company’s stock worth $329,000 after acquiring an additional 86 shares in the last quarter. Cetera Advisor Networks LLC boosted its holdings in Moderna by 0.5% in the fourth quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company’s stock worth $3,088,000 after acquiring an additional 87 shares in the last quarter. Ancora Advisors LLC boosted its holdings in Moderna by 41.2% in the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after acquiring an additional 96 shares in the last quarter. Sunbelt Securities Inc. boosted its holdings in Moderna by 7.5% in the first quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company’s stock worth $211,000 after acquiring an additional 100 shares in the last quarter. Finally, Wetherby Asset Management Inc. boosted its holdings in Moderna by 1.3% in the first quarter. Wetherby Asset Management Inc. now owns 7,722 shares of the company’s stock worth $1,186,000 after acquiring an additional 101 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Canaccord Genuity Group increased their price target on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a report on Friday, February 23rd. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price on the stock in a report on Tuesday, January 2nd. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 price target on shares of Moderna in a research report on Tuesday, April 9th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $125.00 target price on shares of Moderna in a research report on Thursday, March 28th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $126.49.

Moderna Price Performance

Moderna stock opened at $103.44 on Thursday. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $144.93. The business has a 50-day simple moving average of $100.19 and a 200 day simple moving average of $93.59. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. The stock has a market cap of $39.61 billion, a price-to-earnings ratio of -8.34 and a beta of 1.62.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. During the same period in the prior year, the business earned $3.61 EPS. The company’s revenue for the quarter was down 44.9% compared to the same quarter last year. On average, research analysts forecast that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In other news, President Stephen Hoge sold 2,388 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the sale, the president now owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, President Stephen Hoge sold 2,388 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the sale, the president now owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $63,361.90. Following the transaction, the insider now directly owns 8,557 shares of the company’s stock, valued at approximately $809,235.49. The disclosure for this sale can be found here. In the last three months, insiders sold 94,954 shares of company stock worth $9,983,276. 15.70% of the stock is currently owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.